Regulatory Story
Go to market news section View chart   Print
RNS
Redx Pharma plc   -  REDX   

Update on Court Process

Released 07:00 13-Oct-2017

RNS Number : 4892T
Redx Pharma plc
13 October 2017
 

13 October 2017

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

REDX PHARMA PLC (in administration)

("Redx" or "the Company")

 

Permission granted for distribution to Unsecured Creditors

 

Redx, the drug discovery and development company, announces that Jason Baker and Miles Needham of FRP Advisory LLP, joint administrators of the Company and of its subsidiary, Redx Oncology Limited ("Oncology") (together, the "Companies") have applied to the High Court for an order which will enable the Companies to be rescued as going concerns and the Joint Administrators to vacate office.

 

Unless adjourned by the court, the application will be heard on Thursday 26 October 2017.  Assuming that the application is approved by the High Court, the Joint Administrators will subsequently take steps to return control of the Company to the directors, following which the directors will seek to lift the suspension of the Company's ordinary shares.

 

Further announcements will be made in due course.

 

For further information, please contact:

 

Redx Pharma Plc (in administration)


 

Contact for the Joint Administrators:

Chris French

James Rossiter

 

T: + 44 203 005 4000

 

Cantor Fitzgerald Europe (Nomad & Broker)

 

T: +44 20 7894 7000

Phil Davies

 


 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 



About Redx Pharma Plc (in administration)

 

Company website: redxpharma.com

 

Jason Baker and Miles Needham have been appointed as joint administrators of Redx Pharma plc (in administration). The company's affairs, business and property are being managed by the joint administrators.

 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDGGGPCUUPMGAP
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Update on Court Process - RNS